Zacks: Analysts Anticipate Opko Health Inc. (NASDAQ:OPK) Will Announce Earnings of -$0.08 Per Share

Wall Street analysts predict that Opko Health Inc. (NASDAQ:OPK) will post earnings of ($0.08) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Opko Health’s earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.08). Opko Health also posted earnings of ($0.08) per share during the same quarter last year. The business is expected to report its next quarterly earnings results on Wednesday, February 26th.

According to Zacks, analysts expect that Opko Health will report full year earnings of ($0.43) per share for the current financial year, with EPS estimates ranging from ($0.44) to ($0.42). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.27) per share, with EPS estimates ranging from ($0.38) to ($0.22). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Opko Health.

Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). Opko Health had a negative net margin of 30.98% and a negative return on equity of 14.42%. The business had revenue of $228.80 million during the quarter, compared to analysts’ expectations of $225.40 million. During the same quarter in the prior year, the firm posted ($0.05) earnings per share. The firm’s quarterly revenue was down 8.4% on a year-over-year basis.

Several equities analysts have recently weighed in on the company. Piper Jaffray Companies began coverage on Opko Health in a research report on Monday, November 25th. They issued an “overweight” rating and a $2.50 price target for the company. Barrington Research reissued a “buy” rating and set a $4.00 price objective on shares of Opko Health in a report on Thursday, September 12th. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research note on Friday, October 18th. Finally, BidaskClub raised Opko Health from a “sell” rating to a “hold” rating in a report on Thursday, November 21st. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Opko Health currently has a consensus rating of “Buy” and a consensus price target of $2.83.

Shares of NASDAQ:OPK traded up $0.02 during trading on Friday, hitting $1.61. 3,080,442 shares of the company were exchanged, compared to its average volume of 4,753,029. Opko Health has a 52-week low of $1.33 and a 52-week high of $3.93. The stock has a 50 day moving average of $1.60 and a 200 day moving average of $1.92. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.08 and a quick ratio of 0.90. The company has a market cap of $1.07 billion, a PE ratio of -6.44 and a beta of 2.20.

In other Opko Health news, CEO Phillip Md Et Al Frost purchased 50,000 shares of the stock in a transaction on Thursday, December 5th. The shares were purchased at an average price of $1.62 per share, with a total value of $81,000.00. Also, Vice Chairman Jane Ph D. Hsiao purchased 400,000 shares of the company’s stock in a transaction dated Friday, October 25th. The shares were acquired at an average price of $1.50 per share, with a total value of $600,000.00. Following the transaction, the insider now owns 24,475,147 shares in the company, valued at approximately $36,712,720.50. The disclosure for this purchase can be found here. Insiders have purchased a total of 3,590,000 shares of company stock worth $5,369,750 in the last ninety days. 42.25% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Alpha Cubed Investments LLC bought a new stake in Opko Health during the third quarter valued at approximately $25,000. Eqis Capital Management Inc. bought a new stake in shares of Opko Health during the 2nd quarter worth $33,000. Sawtooth Solutions LLC bought a new stake in shares of Opko Health during the 2nd quarter worth $45,000. Kings Point Capital Management bought a new stake in shares of Opko Health during the 2nd quarter worth $45,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. grew its position in Opko Health by 100.0% in the second quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 20,000 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 10,000 shares in the last quarter. 21.61% of the stock is currently owned by institutional investors and hedge funds.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

See Also: How can investors invest in the Euro STOXX 50 Index?

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with's FREE daily email newsletter.